The Picower Institute for Medical Research

Gem Pharmaceuticals, LLC

Other

Xini Zhang

Peter C Ulrich

Anthony Cerami

Richard J Bucala

Helen Vlassara

Michael Peter Vitek

Richard D Olson

The present invention relates generally to the non-enzymatic glycosylation of amyloidogenic proteins and the consequent formation of advanced glycosylation endproducts (AGEs). It has been found that formation of AGE-amyloidogenic proteins can enhance amyloidosis. The invention further relates to compositions and methods for the prevention and treatment of amyloidosis associated with amyloid diseases, particularly neurodegenerative disease and Type II diabetes, and more particularly Alzheimer's disease. In a specific example, aggregation of an amyloidogenic peptide, &bgr;AP, is enhanced by the glycosylation reaction of &bgr;AP to form AGE-&bgr;AP as defined herein. Accordingly, the invention extends to a method for modulating the in vivo aggregation of amyloid polypeptides and associated amyloidosis by controlling the formation and presence of AGE-amyloid polypeptide. A corresponding diagnostic utility comprises the measurement of the course and extent of amyloidosis by a measurement of the presence and amount of AGEs and particularly, AGE-amyloid. An assay is included that may use the AGE-amyloid polypeptide of the present invention to identify disease states characterized by the presence of AGE-amyloid. Additionally, such an assay can be utilized to monitor therapy and thus adjust a dosage regimen for a given disease state characterized by the presence of AGE-amyloid.

Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis

A process for the preparation of 13-deoxy deoxyanthracycline derivatives.

Processes for preparing 13-deoxy anthracycline derivatives

5-imino-13-deoxy anthracycline derivatives, medical uses of 5-imino-13-deoxy anthracycline derivatives and methods for preparing 5-imino-13-deoxy anthracycline derivatives.

5-imino-13-deoxy anthracycline derivatives, their uses, and processes

Compositions and methods for stimulating amyloid removal in

The present invention relates to advanced glycosylation endproducts, and particularly to the use of novel cyclopentenone aminoreductones, 3-alkylamino-2 -hydroxy-4-hydroxymethyl-2-cyclopenten-1-ones. Such AGEs can be used in various diagnostic and therapeutic methods.

3-alkylamino-2-hydroxy-4-hydroxymethyl-2-cyclopenten-1-one advanced

The present invention relates to advanced glycosylation endproducts (AGEs), and particularly to novel cyclopentenone aminoreductones, 3-alkylamino-2-hydroxy-4-hydroxymethyl-2-cyclopenten-1-ones. Such AGEs can be used in various diagnostic and therapeutic methods.

Growing community of inventors

Hoover, AL, United States of America

Xini Zhang